Eptaloprost
Alternative Names: Eptaprost; ZK 979591Latest Information Update: 23 Jun 2004
At a glance
- Originator Bayer Schering Pharma
- Class Antineoplastics; Prostaglandins; Small molecules
- Mechanism of Action Epoprostenol agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders
Most Recent Events
- 15 Jun 2004 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 15 Jun 2004 Discontinued for Cardiovascular disorders in Germany (unspecified route)
- 30 May 2001 Profile reviewed but no significant changes made